- Home
- VRNA vs XP Comparison
VRNA vs XP Comparison
Compare VRNA & XP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- XP
- Stock Information
- Founded
- VRNA 2005
- XP 2001
- Country
- VRNA United Kingdom
- XP Cayman Islands
- Employees
- VRNA N/A
- XP N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- XP Investment Bankers/Brokers/Service
- Sector
- VRNA Health Care
- XP Finance
- Exchange
- VRNA Nasdaq
- XP Nasdaq
- Market Cap
- VRNA 8.3B
- XP 9.8B
- IPO Year
- VRNA 2017
- XP 2019
- Fundamental
- Price
- VRNA $106.27
- XP $19.14
- Analyst Decision
- VRNA Buy
- XP Strong Buy
- Analyst Count
- VRNA 11
- XP 5
- Target Price
- VRNA $114.10
- XP $23.80
- AVG Volume (30 Days)
- VRNA 1.3M
- XP 8.1M
- Earning Date
- VRNA 11-03-2025
- XP 08-18-2025
- Dividend Yield
- VRNA N/A
- XP 7.22%
- EPS Growth
- VRNA N/A
- XP 18.07
- EPS
- VRNA N/A
- XP 1.67
- Revenue
- VRNA $221,673,000.00
- XP $3,085,301,717.00
- Revenue This Year
- VRNA $896.59
- XP $18.43
- Revenue Next Year
- VRNA $77.56
- XP $13.18
- P/E Ratio
- VRNA N/A
- XP $11.22
- Revenue Growth
- VRNA N/A
- XP 6.65
- 52 Week Low
- VRNA $27.54
- XP $10.82
- 52 Week High
- VRNA $106.45
- XP $20.64
- Technical
- Relative Strength Index (RSI)
- VRNA 68.40
- XP 63.29
- Support Level
- VRNA $106.15
- XP $18.75
- Resistance Level
- VRNA $106.42
- XP $19.19
- Average True Range (ATR)
- VRNA 0.19
- XP 0.54
- MACD
- VRNA -0.17
- XP 0.14
- Stochastic Oscillator
- VRNA 76.32
- XP 92.19
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.